Cisatracurium

drugbox
IUPAC_name = 5- [3- [(1"R",2"R")-1- [(3,4-dimethoxyphenyl)methyl] -6,7-
dimethoxy-2-methyl-3,4-dihydro-1"H"-isoquinolin-2-yl]
propanoyloxy] pentyl 3- [(1"R",2"R")-1- [(3,4-dimethoxy
phenyl)methyl] -6,7-dimethoxy-2-methyl-3,4-dihydro-
1"H"-isoquinolin-2-yl] propanoate

---

width = 300
CAS_number = 96946-42-8
ATC_prefix = M03
ATC_suffix = AC11
ATC_supplemental =
PubChem = 62887
DrugBank = APRD00874
C = 53 | H = 72 | N = 2 | O = 12 | charge = +2
molecular_weight = 929.145 g/mol
bioavailability = N/A - IV use only
protein_bound = Unknown due to rapid degradation
metabolism = 80% Hoffman elmination/ Hepatic
elimination_half-life = 20-29 minutes
excretion = 10-15% unchanged
pregnancy_AU =
pregnancy_US =
pregnancy_category = B
legal_AU =
legal_UK =
legal_US =
legal_status =
routes_of_administration = IV only

Cisatracurium (usually as cisatracurium besilate, trade name Nimbex) is a neuromuscular-blocking drug. It is one of the ten isomers of atracurium. Its active metabolites contain less laudanosine which cause hypotension, central nervous system excitement, and seizures than that of atracurium. It is considered an intermediate-acting agent in terms of duration of action.

tructure

It is a bisbenzyltetrahyrdoisoquinolinium agent in the quaternary ammonium compound family.

Metabolism

80% is metabolized to laudanosine via Hofmann elimination (which is dependent on the pH and the temperature of the plasma) and 20% is metabolized hepatically or excreted renally. Since Hofmann elimination is organ-independent, the use of cisatracurium may pose less risk in patients with liver or renal disease than other neuromuscular blockers. 10-15% of the dose is excreted unchanged in the urine.

External links

*
*
*